Evidence map›Paper›PMID 29052780›Full record

ReviewCancer immunology, immunotherapy : CII2018

Immunotherapy for hepatocellular carcinoma patients: is it ready for prime time?

Joseph M Obeid, Paul R Kunk, Victor M Zaydfudim, Timothy N Bullock, Craig L Slingluff, Osama E Rahma

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer immunology, immunotherapy : CII, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Vanadium complex: an appropriate candidate for killing hepatocellular carcinoma cancerous cells.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2018
    Article
  13. Review
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Joseph M ObeidDepartment of Surgery, University of Virginia, Charlottesville, VA, USA.
Paul R KunkDivision of Hematology-Oncology, Department of Medicine, University of Virginia, Charlottesville, VA, USA.
Victor M ZaydfudimDepartment of Surgery, University of Virginia, Charlottesville, VA, USA.
Timothy N BullockDepartment of Pathology, University of Virginia, Charlottesville, VA, USA.
Craig L SlingluffDepartment of Surgery, University of Virginia, Charlottesville, VA, USA.
Osama E RahmaDepartment of Medical Oncology, Dana-Farber Cancer Institute Harvard Medical School, 450 Brookline Avenue, M1B13, Boston, MA, 02215, USA. osamae_rahma@dfci.harvard.edu.

Funding

Women's Oncology Program - WONP30CA044579 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Jay William FOX · 1987 to 2026
$72.1M
Postdoctoral Training Grant for MDs in Surgical Oncology ResearchT32CA163177 · NCI · UNIVERSITY OF VIRGINIA · PI Craig Lee Slingluff, Allan Tsung · 2011 to 2026
$4.6M
NCI NIH HHS P30 CA044579NCI NIH HHS T32 CA163177
6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and the second most common cause of cancer death worldwide. Current treatment options for patients with intermediate and advanced HCC are limited, and there is an unmet need for novel therapeutic approaches. HCC is an attractive target for immunomodulation therapy, since it arises in an inflammatory milieu due to hepatitis B and C infections and cirrhosis. However, a major barrier to the development and success of immunotherapy in patients with HCC is the liver's inherent immunosuppressive function. Recent advances in the field of cancer immunology allowed further characterization of immune cell subsets and function, and created new opportunities for therapeutic modulation of the immune system. In this review, we present the different immune cell subsets involved in potential immune modulation of HCC, discuss their function and clinical relevance, review the variety of immune therapeutic agents currently under investigation in clinical trials, and outline future research directions.

Indexed as

Carcinoma, HepatocellularHumansImmunotherapyLiver NeoplasmsCancer immunologyCancer vaccinesCheckpoint blockadeHepatocellular carcinoma, HCCImmunotherapyReview article

Identifiers

PMID29052780
PMCPMC11028155

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.